Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;30(8):4234-4241.
doi: 10.1007/s00330-020-06799-5. Epub 2020 Mar 31.

Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area

Federica Rossi  1   2 , Lorenzo Torri  3 , Matteo Lambertini  4 , Sara De Giorgis  3 , Massimo Calabrese  5 , Alberto Stefano Tagliafico  3   5
Affiliations

Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area

Federica Rossi et al. Eur Radiol. 2020 Aug.

Abstract

Objectives: The loss of skeletal muscle mass is widely considered a predictor of poor survival and toxicity in breast cancer patients. The aim of this study is to evaluate if there is pectoralis muscle area (PMA) variation, reflecting loss of skeletal muscle mass, on consecutive MRI examinations after neoadjuvant chemotherapy.

Methods: The retrospective study protocol was approved by our institutional review board. A total of n = 110 consecutive patients (mean age 56 ± 11 years) who were treated with neoadjuvant chemotherapy (NAC) for histologically proven primary breast cancer between January 2017 and January 2019 and in whom tumor response was checked with standard breast MRI were included. Two radiologists calculated the pectoralis muscle cross-sectional area before and after NAC.

Results: Time between the MRI examinations, before starting NAC and after completing NAC, was 166.8 ± 50 days. PMA calculated pre-NAC (8.14 cm2) was larger than PMA calculated post-NAC (7.03 cm2) (p < 0.001). According to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, there were no significant differences between responders (complete or partial response) and non-responders (p = 0.362). The multivariate regression analysis did not show any significant relationships between ΔPMA and age, time between MRI exams, estrogen and progesterone receptor status, human epidermal growth factor receptor status (HER-2), Ki-67 expression, lymph node status, RECIST criteria, histological type, average lesion size, molecular categories, and grade. Inter-reader (k = 0.72) and intra-reader agreement (0.69 and 0.71) in PMA assessment were good.

Conclusions: Pectoralis muscle mass varies in breast cancer patients undergoing NAC and this difference can be estimated directly on standard breast MRI.

Key points: • Pectoralis muscle area variation reflects loss of skeletal muscle mass. • Pectoralis muscle area on MRI is reduced after NAC. • Pectoralis muscle mass loss seems independent from other variables.

Keywords: Breast cancer; Chemotherapy; Magnetic resonance imaging.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804 - DOI
    1. Deluche E, Leobon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N (2018) Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 26:861–868 - DOI
    1. Klassen O, Schmidt ME, Ulrich CM et al (2017) Muscle strength in breast cancer patients receiving different treatment regimes. J Cachexia Sarcopenia Muscle 8:305–316 - DOI
    1. Villaseñor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL study. J Cancer Surviv 6:398–406 - DOI
    1. Mazzuca F, Onesti CE, Roberto M et al (2018) Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget 9:25714–25722 - DOI

Substances